Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
QUILLICHEW ER vs ADDERALL 5
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Quillichew ER contains methylphenidate, a central nervous system (CNS) stimulant. The mechanism of action in ADHD is not fully understood, but it is thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron, increasing their availability in the extraneuronal space.
Adderall 5 is a combination of dextroamphetamine and amphetamine, which are central nervous system stimulants. They increase the levels of dopamine and norepinephrine in the synaptic cleft by inhibiting their reuptake and promoting their release from presynaptic neurons.
Attention Deficit Hyperactivity Disorder (ADHD)
Attention Deficit Hyperactivity Disorder (ADHD),Narcolepsy
Initial 20 mg orally once daily, titrate by 10 mg weekly to maximum 60 mg/day (methylphenidate component).
Initial: 5 mg orally once or twice daily; increase by 5 mg increments at weekly intervals. Maximum: 40 mg/day in divided doses.
The terminal elimination half-life of methylphenidate is approximately 3-4 hours in children and 3.5-5 hours in adults. For Quilli Chew ER, the extended-release formulation provides a prolonged absorption phase, with an effective duration of action of up to 12 hours.
Immediate-release: 9–11 hours (mean 10 hours for dextroamphetamine); extended-release: 10–13 hours. Terminal half-life may be prolonged with urinary p H >7.
Methylphenidate is primarily metabolized by deesterification via carboxylesterase 1 (CES1) to ritalinic acid, which is pharmacologically inactive. Minor metabolism via hydroxylation and microsomal oxidation.
Amphetamine is metabolized via CYP2D6, with deamination and oxidation as major pathways.
Quilli Chew ER (methylphenidate extended-release chewable tablet) is primarily eliminated via renal excretion as metabolites (60-80%) and unchanged drug (approx. 10%). Hepatic metabolism accounts for the remainder. Fecal elimination is minimal.
Renal (90% as unchanged drug and metabolites; ~30% unchanged), minor fecal elimination (<5%).
Methylphenidate is approximately 10-33% bound to plasma proteins, primarily albumin. Binding is low and not clinically significant.
~16% bound to plasma proteins (primarily albumin).
Volume of distribution (Vd) for methylphenidate is approximately 2-3 L/kg, indicating extensive tissue distribution. It is not highly bound to tissues.
3.5–4.5 L/kg; indicates extensive tissue distribution (e.g., brain, lungs).
Oral bioavailability of methylphenidate is variable and low, approximately 11-52% due to extensive first-pass metabolism. Quilli Chew ER is designed to deliver a consistent extended-release profile with a bioavailability of about 20-30% relative to immediate-release formulations.
Oral immediate-release: 96–100% (first-pass metabolism minimal); extended-release: approximately 96% relative to immediate-release.
No dosage adjustment recommended for GFR >30 m L/min; avoid in GFR ≤30 m L/min.
GFR 15-29 m L/min: reduce dose by 50%; GFR <15 m L/min: use maximum of 50% of usual dose; not recommended in ESRD.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: not recommended.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: avoid use.
Children ≥6 years: initial 20 mg orally once daily, titrate by 10 mg weekly to max 60 mg/day.
Children 3-5 years: initial 2.5 mg daily, increase by 2.5 mg weekly; max 40 mg/day. Children ≥6 years: initial 5 mg once or twice daily, increase by 5 mg weekly; max 40 mg/day (or 20 mg/day for extended-release).
Start at 10 mg orally once daily, titrate cautiously; monitor for increased sensitivity and cardiovascular effects.
Initiate at 2.5 mg once or twice daily; increase by 2.5-5 mg weekly; monitor for cardiovascular effects and confusion.
QUILLICHEW ER has a high potential for abuse and dependence. Prolonged use may lead to drug dependence. Misuse may cause sudden death or serious cardiovascular adverse events.
Adderall has a high potential for abuse and dependence. Misuse may cause sudden death or serious cardiovascular events.
Serious cardiovascular events: sudden death, stroke, myocardial infarction in patients with pre-existing structural cardiac abnormalities or other serious heart problems.,Blood pressure and heart rate increase; monitor closely.,Psychiatric adverse events: exacerbation of pre-existing psychosis, mania, or aggressive behavior.,Long-term suppression of growth (weight and height) in pediatric patients.,Seizures: use with caution in patients with history of seizures.,Priapism: prolonged, painful erections may occur.,Peripheral vasculopathy: Raynaud's phenomenon.
Serious cardiovascular events including sudden death in patients with pre-existing structural cardiac abnormalities,Blood pressure and heart rate increases,Psychiatric adverse events such as psychosis or mania,Growth suppression in pediatric patients,Seizures,Peripheral vasculopathy including Raynaud's phenomenon,Serotonin syndrome when co-administered with serotonergic drugs
Known hypersensitivity to methylphenidate or any component of the formulation.,Concurrent use with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing MAOI therapy.,Glaucoma.,Motor tics or family history of Tourette's syndrome.,Severe anxiety, tension, or agitation.,Patients with history of drug abuse or dependence.
Advanced arteriosclerosis,Symptomatic cardiovascular disease,Moderate to severe hypertension,Hyperthyroidism,Glaucoma,Agitated states,History of drug abuse,Concurrent use of MAOIs or within 14 days of discontinuing MAOI,Hypersensitivity to amphetamine products
Avoid high-fat meals as they may delay absorption and alter peak concentration. Grapefruit and grapefruit juice may increase methylphenidate levels and should be avoided. Acidic foods (e.g., citrus fruits, colas) can affect drug absorption; maintain a consistent dietary pattern. Alcohol may cause dose dumping and should be avoided.
Avoid acidic foods or vitamin C supplements within 1 hour of dosing as they decrease absorption. Grapefruit may increase drug levels. Caffeine and other stimulants should be limited. Avoid alcohol. High-fat meals may delay onset but not overall absorption.
Pregnancy Category C. First trimester: Possible increased risk of cardiovascular malformations and oral clefts from methylphenidate exposure; however, absolute risk remains low. Second and third trimesters: Risk of preterm birth, low birth weight, and neonatal withdrawal syndrome (including irritability, dysphoria, and poor feeding).
Pregnancy Category C (pre-2015) / Not assigned under current FDA labeling. First trimester: Studies suggest a possible small increased risk of congenital malformations, particularly cardiovascular defects and oral clefts, but absolute risk is low. Second and third trimesters: Exposure may increase risk of preterm delivery, low birth weight, and neonatal withdrawal symptoms including irritability, dysphoria, and feeding difficulties. Chronic use may lead to fetal growth restriction.
Limited data. Methylphenidate is excreted into breast milk. M/P ratio not established. Infant relative dose <1% of maternal weight-adjusted dose. Monitor infant for agitation, insomnia, and poor weight gain. Avoid use in breastfeeding unless clearly necessary.
Amphetamine is excreted into human breast milk. The milk-to-plasma (M/P) ratio is approximately 2.0–3.0. Relative infant dose is estimated at 5–10% of the maternal weight-adjusted dose. Use while breastfeeding is generally not recommended due to potential adverse effects on the infant, including irritability, poor feeding, and insomnia. Consider alternative treatments or discontinue breastfeeding.
Physiologic changes in pregnancy (increased plasma volume, renal clearance, and hepatic metabolism) may reduce methylphenidate levels. Consider increasing dose based on clinical response and tolerability, with gradual titration. Monitor for reduced efficacy in second and third trimesters. Use lowest effective dose.
Pharmacokinetic changes in pregnancy (increased volume of distribution, enhanced hepatic metabolism, and increased renal clearance) can lower amphetamine plasma concentrations. Dose adjustments may be necessary to maintain therapeutic effect; however, formal guidelines are lacking. Use the lowest effective dose and monitor clinical response. Avoid during pregnancy unless potential benefits outweigh risks.
QUILLICHEW ER is an extended-release formulation of methylphenidate, a CNS stimulant, indicated for ADHD. Chewing or crushing the tablet destroys the extended-release mechanism, risking dose dumping. The tablet shell may appear in stool but is not medically significant. Monitor for growth suppression in children, weight loss, and potential for abuse. Avoid use in patients with glaucoma, motor tics, or family history of Tourette's syndrome. Use caution in patients with hypertension, tachycardia, or pre-existing psychiatric disorders like bipolar disorder or psychosis. Assess for potential drug interactions, particularly with MAOIs, anticoagulants (may decrease effect), and vasopressors.
ADDERALL 5 (amphetamine/dextroamphetamine) is a CNS stimulant. Note that 5 mg is a low starting dose; titrate based on response and tolerability. Avoid use in patients with structural cardiac abnormalities, glaucoma, hyperthyroidism, or history of drug abuse. Monitor for hypertension, tachycardia, and psychiatric symptoms. Can worsen tics or Tourette syndrome. Use with caution with MAOIs (risk of hypertensive crisis).
Take exactly as prescribed. Do not chew, crush, or split the tablet; swallow whole with liquid.,The tablet shell may appear in your stool, but the medication is absorbed; this is normal.,Do not take in the evening to prevent insomnia. Take in the morning with or without food.,Avoid alcohol while taking this medication; alcohol can affect the extended-release properties.,Common side effects include decreased appetite, trouble sleeping, dry mouth, and headache.,Report any chest pain, shortness of breath, fainting, or severe dizziness immediately.,Store at room temperature, protect from moisture, and keep out of reach of children.,Your doctor will monitor your blood pressure, heart rate, and weight regularly.,Do not stop abruptly; tapering may be needed to avoid withdrawal or rebound depression.
Take exactly as prescribed; do not increase dose without consulting doctor.,Swallow tablet whole; do not crush or chew.,Avoid taking late in the day to prevent insomnia.,May cause dizziness; avoid driving if affected.,Report chest pain, shortness of breath, or fainting.,May be habit-forming; do not share with others.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about QUILLICHEW ER vs ADDERALL 5, answered by our medical review team.
QUILLICHEW ER is a CNS Stimulant that works by Quillichew ER contains methylphenidate, a central nervous system (CNS) stimulant. The mechanism of action in ADHD is not fully understood, but it is thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron, increasing their availability in the extraneuronal space.. ADDERALL 5 is a CNS Stimulant that works by Adderall 5 is a combination of dextroamphetamine and amphetamine, which are central nervous system stimulants. They increase the levels of dopamine and norepinephrine in the synaptic cleft by inhibiting their reuptake and promoting their release from presynaptic neurons.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between QUILLICHEW ER and ADDERALL 5 depend on the specific clinical indication. These are both CNS Stimulant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of QUILLICHEW ER is: Initial 20 mg orally once daily, titrate by 10 mg weekly to maximum 60 mg/day (methylphenidate component).. The standard adult dose of ADDERALL 5 is: Initial: 5 mg orally once or twice daily; increase by 5 mg increments at weekly intervals. Maximum: 40 mg/day in divided doses.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between QUILLICHEW ER and ADDERALL 5 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. QUILLICHEW ER is classified as Category C. Pregnancy Category C. First trimester: Possible increased risk of cardiovascular malformations and oral clefts from methylphenidate exposure; however, absolute risk remains low. Se. ADDERALL 5 is classified as Category C. Pregnancy Category C (pre-2015) / Not assigned under current FDA labeling. First trimester: Studies suggest a possible small increased risk of congenital malformations, particularl. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.